Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Bartlett

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Child Psychiatry and Human Development|January 1, 1976
Negotiating educational programs for children with developmental disorders: assessment, interpretation, demonstration, support (AIDS)C H Bartlett, D J O'Grady
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trialN Harbeck, S Iyer, N Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Child Psychiatry and Human Development|January 1, 1976
Negotiating educational programs for children with developmental disorders: assessment, interpretation, demonstration, support (AIDS)C H Bartlett, D J O'Grady
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trialN Harbeck, S Iyer, N Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Pageof 1